mRNA LIGHTNING PLATFORM
DISCOVERY OF SMALL MOLECULE mRNA DRUGS AND THEIR MECHANISMS OF ACTION
HIGH SCALE
PHENOTYPIC SCREENING
TESTING THE EFFECT OF COMPOUNDS ON mRNA BIOLOGY
Post transcription through translation
MILLIONS OF
mRNA IMAGES
VISUALIZING THE
mRNA LIFE CYCLE
ANALYZED WITH MOAi TECHNOLOGY
USING AI TO ELUCIDATE
THE MECHANISM OF ACTION
Delivering multiple chemistries…
Discovering multiple MOAs…
Early de-risking of projects with multiple shots on goal
PIPELINE OF 20 PROGRAMS
BIG PHARMA PARTNERSHIPS

Anima Biotech mRNA Lightning Platform

We are advancing mRNA Lightning, a novel platform for the discovery of small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using AI to elucidate the mechanism of action of active molecules. We develop our own pipeline and partner with pharma on additional targets.

A unique approach at the intersection of mRNA biology and Artificial Intelligence

Our Pharma Partners

For partnering inquiries, please contact [email protected].

mRNA Lightning Platform

Discovery of small molecule mRNA drugs and their mechanisms of action with automated high scale phenotypic screening in live mRNA biology and MOAi technology that uses AI to elucidate the mechanism of action of active molecules.

- AI driven MOA elucidation
AI Image Analysis MOA recognition
Machine Learning Guided MOA assays
mRNA images
High content imaging
High scale automated screening
Plate tower
Robot
Compound library
Automated mRNA Biology phenotypic screening
Cerebio Bioinformatics algorithms that select signature tRNA pair for an mRNA of interest
TranslationLight High content screening for mRNA translation modulators
Brightny Cloud-based big data AI mRNA image analysis identifies active and selective molecules
Compass Mechanism of action and Target ID identification
Cloud Cloud-based mRNA high scale data analysis identifies active and selective mRNA biology modulators.
mRNA images 50 million mRNA images are uploaded to the cloud server for analysis
High content imaging 50 million mRNA images are uploaded to the cloud server for analysis
High scale automated screening Fully automated screen running 24/7 for 3 weeks
Plate Tower +250,000 diverse drug-like small molecules
Robot Fully automated screen running 24/7 for 3 weeks
Compound library +250,000 diverse drug-like small molecules

Discovery of mRNA Biology modulators

Anima's discovery process for selective mRNA biology modulators relies on our proprietary interconnected technologies.

Cerebio runs to produce an in-depth analysis of the mRNA of interest and selects its signature tRNA pair that enables us to visualize mRNA translation in live biology.

Anima's T-Light technologies, TranslationLight and TranscriptLight, are our primary screening assays used for the discovery of mRNA biology modulators. They capture millions of images that show the effect on mRNA biology of hundreds of thousands of compounds from our library.

The images captured during screening are automatically uploaded to the cloud for analysis by BrightNy, which selects the most promising hit compounds using high scale mRNA data analysis. All these technologies feed and interact at every step with our Compass MOAi that runs alongside the discovery process. AI driven MOA elucidation starts as early as hit generation, allowing us to de-risk compounds and progress them at an unprecedented success rate.

Watch Movie: Identification of active and selective mRNA biology modulators

We are leveraging AI to understand where and how our small molecules work along the mRNA life cycle

AI driven MOA elucidation

AI Image Analysis
Billions of mRNA images
MOA recognition
Machine Learning Guided MOA assays

mRNA Biology Modulators Pipeline

With our unique approach, we were able to develop a broad pipeline of small molecule mRNA drugs, advancing 20 discovery programs across therapeutic areas at unparalleled speed and success rate.

Anima wholly owned pipeline programs are in Fibrosis (Collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc mRNA biology modulators and mutation agnostic mKras mRNA biology modulators), and Neuroscience (Tau - Alzheimer's disease and Pain - Nav1.7 mRNA biology modulators). In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly, Takeda Pharmaceuticals, and Abbvie.

Indication Target
Discovery
Optimization
IND enabling
Immunology
Lung fibrosis Collagen-1 1
Multiple fibrosis 2
Multiple fibrosis 3
Undisclosed abbvie logo 4
Oncology
Solid tumors c-Myc 5
Lymphoma 6
c-Myc tumors 7
Neuroblastoma Undisclosed 8
mKRAS tumors mKRAS 9
Undisclosed abbvie logo 10
Undisclosed 11
Neuroscience
Alzheimer TAU 12
Pain Nav 1.7 13
Undisclosed 14
Undisclosed takeda logo 15
Undisclosed 16
Huntington mHTT 17
Undisclosed lilly logo 18
Undisclosed 19
Undisclosed 20
Area Indication mRNA modulation Target
Discovery
Optimization
IND enabling
Immunology Lung fibrosis Collagen-1 1
Multiple fibrosis 2
Multiple fibrosis 3
  Undisclosed abbvie logo 4
Oncology Solid tumors c-Myc 5
Lymphoma 6
c-Myc tumors 7
Neuroblastoma Undisclosed 8
mKRAS tumors mKRAS 9
  Undisclosed abbvie logo 10
  Undisclosed 11
Neuroscience Alzheimer TAU 12
Pain Nav 1.7 13
  Undisclosed 14
  Undisclosed takeda logo 15
  Undisclosed 16
Huntington mHTT 17
  Undisclosed lilly logo 18
  Undisclosed 19
  Undisclosed 20

17 Scientific Collaborations

15 Peer Reviewed Publications

Coverage

News & Events

  • AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

    When: Jan. 10th, 2023

    AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie exclusive rights to license and further develop and commercialize the programs.

    Download Press Release »

  • Biotech Showcase 2023

    When: Jan. 10th, 2023 - Jan. 11th, 2023
    Where: San Francisco, CA

    Anima Biotech will be attending this year’s Biotech Showcase and is looking forward to connecting with other industry experts.  Our chief business officer, Kevin Pong, Ph.D., will give a corporate presentation on Jan. 9th at 9:45 A.M. PST highlighting our unique approach to the discovery of small molecule mRNA drugs.

    Visit the conference website »

  • 5th RNA Targeting Drug Development Summit

    When: Dec. 13th, 2022 - Dec. 15th, 2022
    Where: Boston, MA

    Anima Biotech has been invited to participate in a panel discussion and presentation at the 5th RNA Targeting Drug Development Summit. Our chief business officer, Kevin Pong, Ph.D., will participate in the Biopharma & Investment Partnerships panel – Exploring the Future of RNA Investment & Collaborations Space for Small Molecule on Dec. 14th at 11:50 A.M.

    Visit the conference website »